Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/GMR/GMR-alpha/SMDP4/alphaGMR for drug discovery and mechanism of action (MOA) research

Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/GMR/GMR-alpha/SMDP4/alphaGMR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sargramostim (tradename Leukine) is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator.

Sargramostim is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. Sargramostim therapy has been promising in the adjuvant setting with vaccines and for anti-microbial-resistant infections and treating autoimmune pulmonary alveolar proteinosis and gastrointestinal, peripheral arterial and neuro-inflammatory diseases. It also may be useful as an adjuvant in anti-cancer immunotherapy. Sargramostim increases the cytotoxic activity of monocytes toward certain malignant cell lines and activates polymorphonuclear neutrophils to inhibit the growth of cancer cells. GM-CSF can stimulate the proliferation of leukemias; most require GM-CSF as a growth factor.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-986-1mg	1mg	3090
GMP-Bios-INN-986-10mg	10mg	Inquiry
GMP-Bios-INN-986-100mg	100mg	Inquiry
GMP-Bios-INN-986-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/GMR/GMR-alpha/SMDP4/alphaGMR
INN Name	Sargramostim
Target	CSF2RA
Format	Recombinant Protein
Derivation	0
Species Reactivity	human
CH1 Isotype	CSF2 (colony stimulating factor 2 (granulocyte- macrophage), granulocyte- macrophage colony stimulating factor, GM-CSF) recombinant
VD LC	CSF2 (colony stimulating factor 2 (granulocyte- macrophage), granulocyte- macrophage colony stimulating factor, GM-CSF) recombinant
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Berlex Inc. (Wayne NJ USA) / Genzyme Corp. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0